Allakos Inc.(ALLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALLK Allakos Inc.

Market Closed 09-27 16:00:00 EDT

0.6361

+0.0606

+10.53%

盘后0.6361

+0.00000.00%

18:02 EDT

High0.6701	Low0.5750	Vol359.54K
Open0.5880	D1 Closing0.5755	Amplitude16.52%
Mkt Cap56.52M	Tradable Cap37.67M	Total Shares88.85M
T/O226.85K	T/O Rate0.61%	Tradable Shares59.22M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ALLK","market":"US","secType":"STK","nameCN":"Allakos Inc.","latestPrice":0.6361,"timestamp":1727467200000,"preClose":0.5755,"halted":0,"volume":359535,"hourTrading":{"tag":"盘后","latestPrice":0.6361,"preClose":0.6361,"latestTime":"18:02 EDT","volume":187,"amount":118.4442,"timestamp":1727474566588},"delay":0,"floatShares":59217489,"shares":88850713,"eps":-2.347129,"marketStatus":"Market Closed","change":0.0606,"latestTime":"09-27 16:00:00 EDT","open":0.588,"high":0.670097,"low":0.575,"amount":226847.87120325002,"amplitude":0.165242,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.347129,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1727683200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1531972800000,"exchange":"NASDAQ","adjPreClose":0.5755,"preHourTrading":{"tag":"盘前","latestPrice":0.573,"preClose":0.5755,"latestTime":"09:10 EDT","volume":204,"amount":118.46049479999999,"timestamp":1727442645213},"postHourTrading":{"tag":"盘后","latestPrice":0.6361,"preClose":0.6361,"latestTime":"18:02 EDT","volume":187,"amount":118.4442,"timestamp":1727474566588},"volumeRatio":0.9522424938910781,"impliedVol":1.916,"impliedVolPercentile":0.5516},"requestUrl":"/m/hq/s/ALLK/tweets","defaultTab":"tweets","newsList":[{"id":"2460241831","title":"Allakos Gets Nasdaq Noncompliance Notice on Minimum Bid Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2460241831","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460241831?lang=en_us&edition=fundamental","pubTime":"2024-08-17 00:10","pubTimestamp":1723824656,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["LU2210150020.SGD","LU2210149790.SGD","BK4112","IE00BKPKM429.USD","QLD","TQQQ","SQQQ","NDAQ","BK4588","QID","PSQ","LU2095319765.USD","QQQ",".IXIC","BK4585","NQmain","MNQmain","ALLK","BK4139"],"gpt_icon":0},{"id":"2460241361","title":"Allakos Gets Nasdaq Noncompliance Notice on Minimum Bid Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2460241361","media":"MT Newswires Live","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460241361?lang=en_us&edition=fundamental","pubTime":"2024-08-17 00:10","pubTimestamp":1723824656,"startTime":"0","endTime":"0","summary":"Allakos  said Friday it received a noncompliance notice from Nasdaq on Tuesday for not meeting the minimum bid price of $1 per share for continued listing on the exchange.The company said it has until Feb. 10 to regain compliance with the Nasdaq listing rule.Allakos said the Nasdaq notice has no immediate effect on the listing of its common stock.Shares of Allakos were down 2.3% in recent Friday trading.Price: 0.64, Change: -0.02, Percent Change: -2.28","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4139","NQmain","MNQmain","SQQQ","IE00BKPKM429.USD","NDAQ","LU2210150020.SGD","TQQQ","BK4112",".IXIC","PSQ","LU2095319765.USD","QID","QLD","ALLK","BK4588","LU2210149790.SGD"],"gpt_icon":1},{"id":"2457835303","title":"Allakos GAAP EPS of -$0.30","url":"https://stock-news.laohu8.com/highlight/detail?id=2457835303","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457835303?lang=en_us&edition=fundamental","pubTime":"2024-08-08 13:42","pubTimestamp":1723095724,"startTime":"0","endTime":"0","summary":"Allakos press release : Q2 GAAP EPS of -$0.30. Allakos ended the second quarter of 2024 with $123.1 million in cash, cash equivalents and investments resulting in a net decrease in cash, cash equivalents and investments of $16.2 million during the second quarter of 2024.  The Company reiterates that the restructuring activities will extend the cash runway into mid-2026 and continues to expect to end 2024 with total cash, cash equivalents and investments in the range of $81 to $86 million.  The Company reiterates that an estimated $30 million of closeout, severance and other costs will be paid in 2024 in connection with exiting the lirentelimab development program, of which we have spent $13 million to date in the first six months of 2024. Approximately $1 million of these payments were made in the second quarter of 2024.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4136813-allakos-gaap-eps-of--030","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["ALLK","BK4139"],"gpt_icon":0},{"id":"2457002578","title":"TD Cowen Sticks to Its Hold Rating for Allakos (ALLK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2457002578","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457002578?lang=en_us&edition=fundamental","pubTime":"2024-08-08 07:56","pubTimestamp":1723074990,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Joseph Thome maintained a Hold rating on Allakos (ALLK – Research Report) today. The company’s shares closed today at $0.71. Accor...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-its-hold-rating-for-allakos-allk?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-its-hold-rating-for-allakos-allk?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALLK","COWN","TD"],"gpt_icon":0},{"id":"2457870141","title":"Allakos Inc reports results for the quarter ended in June - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2457870141","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457870141?lang=en_us&edition=fundamental","pubTime":"2024-08-08 05:05","pubTimestamp":1723064710,"startTime":"0","endTime":"0","summary":"* Allakos Inc    reported a quarterly adjusted loss of 30 cents per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of -41 cents.  The mean e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Allakos Inc reports results for the quarter ended in June - Earnings Summary","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLK"],"gpt_icon":0},{"id":"2457872356","title":"Allakos Q2 EPS $(0.30) Beats $(0.34) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2457872356","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457872356?lang=en_us&edition=fundamental","pubTime":"2024-08-08 04:26","pubTimestamp":1723062399,"startTime":"0","endTime":"0","summary":"Allakos (NASDAQ:ALLK) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.34) by 11.76 percent. This is a 26.83 percent increase over losses of $(0.41) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/08/40234031/allakos-q2-eps-0-30-beats-0-34-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Allakos Q2 EPS $(0.30) Beats $(0.34) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLK"],"gpt_icon":0},{"id":"2457872611","title":"Allakos Qtrly Shr Loss $0.30","url":"https://stock-news.laohu8.com/highlight/detail?id=2457872611","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457872611?lang=en_us&edition=fundamental","pubTime":"2024-08-08 04:02","pubTimestamp":1723060920,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240807:nTUA9B4SLM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALLK"],"gpt_icon":0},{"id":"2457638872","title":"Allakos Inc: Reiterates That Restructuring Activities Will Extend Cash Runway Into Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2457638872","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457638872?lang=en_us&edition=fundamental","pubTime":"2024-08-08 04:02","pubTimestamp":1723060920,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240807:nTUA9B4SLM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALLK","BK4139"],"gpt_icon":0},{"id":"2457724954","title":"Allakos Inc    expected to post a loss of 33 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2457724954","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457724954?lang=en_us&edition=fundamental","pubTime":"2024-08-05 20:38","pubTimestamp":1722861487,"startTime":"0","endTime":"0","summary":"* Allakos Inc     is expected to show no change in quarterly revenue when it reports  results on August 7 (estimated) for the period ending June 30 2024   *    * LSEG's mean analyst estimate for Allak","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Allakos Inc    expected to post a loss of 33 cents a share - Earnings Preview","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLK"],"gpt_icon":0},{"id":"2456477211","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2456477211","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2456477211?lang=en_us&edition=fundamental","pubTime":"2024-08-02 18:00","pubTimestamp":1722592800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AESI","DH","XGN","CRD.A","MTRN","HLIO","CSTL","AMPH","IIPR","AES","SNCY","BTSG","AAN","DCTH","ANNX","PRGO","MITT","RPID","AGM","AGM.A","BRBR","IGMS","KMPR","TIXT","ABG","CRD.B","MGA","SRCL","MOG.B","TILE","BWXT","BNTX","SQSP","ARES","GPMT","PWP","ANVS","ATXS","ALLK","OMI","PRLB","ATRA","FANG","SMFG","ANAB","CHGG","EHC","APLE","BMRN","MOG.A"],"gpt_icon":0},{"id":"2453031126","title":"Can Allakos (NASDAQ:ALLK) Afford To Invest In Growth?","url":"https://stock-news.laohu8.com/highlight/detail?id=2453031126","media":"Simply Wall St.","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2453031126?lang=en_us&edition=fundamental","pubTime":"2024-07-23 20:33","pubTimestamp":1721738023,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.Given this risk, we thought we'd take a look at whether Allakos  shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.On this analysis of Allakos' cash burn, we think its cash burn reduction was","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/allakos-nasdaq-allk-afford-invest-123343490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2210150020.SGD","BK4112","QID","MNQmain","QLD","BK4588","LU2095319765.USD","BK4585","ALLK",".IXIC","LU2210149790.SGD","NQmain","SQQQ","TQQQ","NDAQ","BK4139","CRM","PSQ"],"gpt_icon":1},{"id":"2452481602","title":"Allakos Is Maintained at Hold by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2452481602","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2452481602?lang=en_us&edition=fundamental","pubTime":"2024-07-18 21:25","pubTimestamp":1721309100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALLK/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 18, 2024 09:25 ET (13:25 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLK","BK4139"],"gpt_icon":0},{"id":"2446831039","title":"Allakos drops after early-stage results for lead asset","url":"https://stock-news.laohu8.com/highlight/detail?id=2446831039","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2446831039?lang=en_us&edition=fundamental","pubTime":"2024-06-27 02:34","pubTimestamp":1719426882,"startTime":"0","endTime":"0","summary":"Allakos  shares dropped on Wednesday after the biotech posted data from a Phase 1 trial for AK006, its most advanced drug candidate targeted at immune-mediated diseases such as chronic spontaneous urticaria . Citing data from healthy volunteers, the San Carlos, California-based biotech said that trial subjects tolerated up to 720 mg of AK006 in single and multiple doses, indicating no serious adverse events.  There were no treatment-emergent adverse events that forced trial participants to discontinue the therapy, and there were no toxicities, the company added. Today’s data came from a study testing intravenous and subcutaneous doses of AK006 in healthy participants and CSU patients. The readout represented healthy volunteers who received intravenous AK006 or placebo. Data from CSU patients receiving the IV form of the therapy is expected later this year.","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1028830260/image_1028830260.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1028830260/image_1028830260.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4119707-allakos-stock-drops-data-lead-asset","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["ALLK","BK4139"],"gpt_icon":0},{"id":"2446313104","title":"Allakos Price Target Maintained With a $3.00/Share by JMP Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2446313104","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2446313104?lang=en_us&edition=fundamental","pubTime":"2024-06-27 00:11","pubTimestamp":1719418260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALLK/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 26, 2024 12:11 ET (16:11 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JMP","ALLK"],"gpt_icon":0},{"id":"2446874973","title":"Allakos Reveals New Corporate Strategy and Performance Insights","url":"https://stock-news.laohu8.com/highlight/detail?id=2446874973","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2446874973?lang=en_us&edition=fundamental","pubTime":"2024-06-26 04:50","pubTimestamp":1719348613,"startTime":"0","endTime":"0","summary":"Allakos (ALLK) just unveiled an update. Allakos Inc. has unveiled a refreshed corporate presentation, offering investors and market watchers a new ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/allakos-reveals-new-corporate-strategy-and-performance-insights?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/allakos-reveals-new-corporate-strategy-and-performance-insights?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALLK","BK4139"],"gpt_icon":0},{"id":"2446187991","title":"BRIEF-Allakos Says AK006 Well-Tolerated In Ongoing Phase 1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2446187991","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2446187991?lang=en_us&edition=fundamental","pubTime":"2024-06-26 04:24","pubTimestamp":1719347087,"startTime":"0","endTime":"0","summary":"June 25  - Allakos Inc   :   * ALLAKOS ANNOUNCES POSITIVE RESULTS FROM ITS ONGOING PHASE 1 TRIAL OF AK006 IN HEALTHY VOLUNTEERS, WITH AK006 DEMONSTRATING HIGH RECEPTOR OCCUPANCY ON MAST CELLS AND A FAVORABLE SAFETY PROFILE   * ALLAKOS INC: AK006 WAS WELL-TOLERATED WITH A FAVORABLE SAFETY PROFILE   * ALLAKOS INC - AK006 WAS WELL-TOLERATED WITH A FAVORABLE SAFETY PROFILE -   * ALLAKOS INC - AK006 WAS WELL-TOLERATED WITH A FAVORABLE SAFETY PROFILE   * ALLAKOS INC - AK006 ACHIEVED SERUM CONCENTRATIONS CONSISTENT WITH LEVELS DEMONSTRATING INHIBITORY ACTIVITY IN PRECLINICAL EXPERIMENTS   * ALLAKOS INC - AK006 SHOWED DOSE LINEAR EXPOSURE AND WITH AN ESTIMATED HALF-LIFE OF 21 DAYS FOR 720 MG IV DOSE   * ALLAKOS-  IN PHASE 1 STUDY RESULTS AK006 ACHIEVED SERUM CONCENTRATIONS CONSISTENT WITH THOSE SHOWING MAST CELL INHIBITION IN PRECLINICAL EXPERIMENTSSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLK"],"gpt_icon":0},{"id":"2446879543","title":"Allakos Reports 'Positive' Results From Phase 1 Trial of Antibody That Inhibits Mast Cells","url":"https://stock-news.laohu8.com/highlight/detail?id=2446879543","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2446879543?lang=en_us&edition=fundamental","pubTime":"2024-06-26 04:21","pubTimestamp":1719346896,"startTime":"0","endTime":"0","summary":"Allakos  reported \"positive\" results late Tuesday from its single and multiple ascending phase 1 study of intravenous AK006, a monoclonal antibody that selectively inhibits mast cells, in healthy volunteers.The company said inappropriate activation of mast cells is a pathogenic driver of multiple diseases, including chronic spontaneous urticaria, food allergy, and asthma.It said single and multiple doses of up to 720 milligrams were \"well tolerated with a favorable safety profile.\" AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments.The company said skin biopsies from subjects treated with AK006 showed \"high receptor occupancy.\"Shares of the company slumped 15% in after-hours activity.Price: 1.0000, Change: -0.18, Percent Change: -15.25","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ALLK"],"gpt_icon":0},{"id":"2446687950","title":"Allakos Reports 'Positive' Results From Phase 1 Trial of Antibody That Inhibits Mast Cells","url":"https://stock-news.laohu8.com/highlight/detail?id=2446687950","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2446687950?lang=en_us&edition=fundamental","pubTime":"2024-06-26 04:21","pubTimestamp":1719346896,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK4139","ALLK"],"gpt_icon":0},{"id":"2446876649","title":"Allakos-  in Phase 1 Study Results Ak006 Achieved Serum Concentrations Consistent With Those Showing Mast Cell Inhibition in Preclinical Experiments","url":"https://stock-news.laohu8.com/highlight/detail?id=2446876649","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2446876649?lang=en_us&edition=fundamental","pubTime":"2024-06-26 04:02","pubTimestamp":1719345720,"startTime":"0","endTime":"0","summary":"Allakos-  in Phase 1 Study Results Ak006 Achieved Serum Concentrations Consistent With Those Showing Mast Cell Inhibition in Preclinical Experiments","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240625:nTUA6NSNRC:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALLK"],"gpt_icon":0},{"id":"2446876539","title":"Allakos Inc - Ak006 Was Well-Tolerated With a Favorable Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2446876539","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2446876539?lang=en_us&edition=fundamental","pubTime":"2024-06-26 04:02","pubTimestamp":1719345720,"startTime":"0","endTime":"0","summary":"Allakos Inc - Ak006 Was Well-Tolerated With a Favorable Safety Profile","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240625:nTUA6NSNRC:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALLK"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.allakos.com","stockEarnings":[{"period":"1week","weight":0.1736},{"period":"1month","weight":-0.1483},{"period":"3month","weight":-0.3639},{"period":"6month","weight":-0.4952},{"period":"1year","weight":-0.735},{"period":"ytd","weight":-0.767}],"compareEarnings":[{"period":"1week","weight":0.0056},{"period":"1month","weight":0.0235},{"period":"3month","weight":0.05},{"period":"6month","weight":0.0924},{"period":"1year","weight":0.3335},{"period":"ytd","weight":0.2022}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.248014},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.072416},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.117765},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.025548},{"month":5,"riseRate":0.333333,"avgChangeRate":0.012634},{"month":6,"riseRate":0.5,"avgChangeRate":-0.038115},{"month":7,"riseRate":0.5,"avgChangeRate":-0.009175},{"month":8,"riseRate":0.571429,"avgChangeRate":0.233613},{"month":9,"riseRate":0.428571,"avgChangeRate":0.013033},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.023477},{"month":11,"riseRate":0.833333,"avgChangeRate":0.180786},{"month":12,"riseRate":0.666667,"avgChangeRate":-0.070932}],"exchange":"NASDAQ","name":"Allakos Inc.","nameEN":"Allakos Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Allakos Inc.(ALLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Allakos Inc.(ALLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Allakos Inc.,ALLK,Allakos Inc.股票,Allakos Inc.股票老虎,Allakos Inc.股票老虎国际,Allakos Inc.行情,Allakos Inc.股票行情,Allakos Inc.股价,Allakos Inc.股市,Allakos Inc.股票价格,Allakos Inc.股票交易,Allakos Inc.股票购买,Allakos Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Allakos Inc.(ALLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Allakos Inc.(ALLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}